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Alternative splicing of the full-length, primary transcript into numerous subgenomic mRNAs is one way that lentiviral gene
expression is regulated. Because the behaviors of different viral isolates might reflect in part differences in splicing, we
investigated the patterns of splice site utilization by simian immunodeficiency viruses (SIVs) originally isolated from sooty
mangabey monkeys (Cercocebus atys). We used reverse transcription–polymerase chain reaction (RT–PCR), molecular
cloning, and DNA sequencing approaches to characterize SIVdeltaB670, a pathogenic and neurovirulent isolate, and
SIVsmmH4, a related molecular clone. The majority of randomly selected SIVdeltaB670 and SIVsmmH4 partial cDNAs
contained tat, rev, nef, and long terminal repeat (LTR) intron splice donor and acceptor sites positioned as expected based
on the proviral sequence of SIVsmmH4. Nearly all (87%) of the partial cDNAs analyzed contained a spliced LTR intron. A
greater number of partial cDNAs derived from SIVdeltaB670–infected cells contained putative alternatively spliced introns
in comparison to SIVsmmH4, including two previously undocumented splice junctions involving the LTR intron splice donor.
These data provide the first comprehensive analysis of splice site utilization by an isolate of SIV in comparison to a related
molecular clone and the first characterization of SIVsmm splice site utilization. q 1996 Academic Press, Inc.
Infection by lentiviruses can lead to a spectrum of viral and models of HIV-1 latency (17, 18), and although some
in vivo studies have shown a similar shift (18, 19) otherreplication states ranging from latent to fully productive
infections, both in the host organism and in individual studies have not supported this conclusion (20, 21). The
patterns of splicing exhibited by HIV-1 and SIVmac arecells (1–4). The regulation of lentiviral gene expression
is dependent on many host cell and viral factors (5) and complex and characterizations of these patterns have
indicated that more than 20 different mRNAs can be pro-once a provirus is transcriptionally active, alternative
splicing of viral RNA is one mechanism of regulation. duced from the primary transcript (9, 10).
Such studies have thus far not included SIVs (SIVsmm)The human immunodeficiency viruses (HIV-1 and HIV-
2) and simian immunodeficiency viruses (SIV) encode a derived from sooty mangabey monkeys (Cercocebus
atys), which have been molecularly cloned and se-single full-length transcript that is processed by the cellu-
lar splicing machinery and associated cellular and viral quenced and are highly related to SIVmac and HIV-2
(22–24). Included in the SIVsmm group of viruses arefactors to give rise to intermediate and short size classes
of viral mRNAs (6 – 15). Included among the short class both pathogenic and nonpathogenic molecular clones
and pathogenic isolates, such as the acutely lethalof viral transcripts are the tat and rev mRNAs, which are
essential for viral replication, and nef, which is required SIVsmmPBj (25). We have used reverse transcription –
polymerase chain reaction (RT–PCR), cloning and se-for infection and disease induction by SIVmac in adult
rhesus macaques (16). The regulation of gene expres- quence analyses to compare the patterns of splice site
utilization by the uncloned, pathogenic isolate ofsion through alternative splicing of the primary transcript
is not completely understood, although the contributions SIVsmm, SIVdeltaB670 (26, 27), to the minimally patho-
genic SIVsmmH4 molecular clone for which the entireof Rev to increased accumulation of singly spliced and
unspliced viral RNAs are well characterized (for a review proviral sequence has been determined (24).
As a first step toward characterizing splice site utiliza-see Ref. 5). Temporal shifts in the pattern of viral RNA
splicing from predominantly short (tat, rev, and nef ) tion by SIVdeltaB670, we PCR amplified, subcloned, and
DNA sequenced the region of proviral DNA surroundingmRNAs to intermediate (env, vif, vpr, and vpu) and full-
length mRNAs have been described in in vitro infections the major subgenomic splice donor. Determination of
these sequences was necessary to eventually define
exon/exon junctions, particularly because there are no1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (612) 626-0623. published seqence data for full-length viruses contained
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FIG. 1. Amplification strategy and sequence characterization of SIVdeltaB670 viral DNA sequences surrounding the major subgenomic splice
donor. (A) Shown is a schematic of the SIV genome and spliced nef, rev, and tat mRNAs. Primers used for amplification of SIV viral DNA were
a1597 [5*-GAAGACCCTGGTCTGTTAGGA-3*, positions 753–773 of SIVsmmH4 (24)] and a1601 [5*-CTGTTCCTGTTTCCACCACTA-3*, positions 1391–
1371]. Primers used for amplification of reverse-transcribed SIV RNA were z3086, z3087, PCRAR, PCR25, and PCRTAT5*. (B) Sequences contained
in four representative PCR clones generated with primer pair a1597 and a1601 using DNA isolated from CEM1174 cells 7 days after infection with
SIVdeltaB670 are shown in comparison to the same sequences from SIVsmmH4, SIVsmmPBj14, and SIVsmm9. Computer alignments of DNA
sequences were performed using the Molecular Biology Information Resource (MBIR; Baylor College of Medicine, Houston, TX) software package.
The relative frequencies of the 24 SIVdeltaB670 clones are shown on the right and putative intron sequences are boxed. Dots represent sequence
identity with the SIVsmmH4 reference sequence and dashes represent sequence gaps. Nucleotide positions follow that for SIVsmmH4 (24).
in the SIVdeltaB670 isolate (26, 27). PCR was performed but one between SIVdeltaB670 and SIVsmmH4 in this
region were located in the putative intron. In this 130-on genomic DNA purified soon (7 days) after infection
of CEM1174 cells (28) with the SIVdeltaB670 isolate to nucleotide region a 2-nucleotide insertion (position 994)
was unique to SIVdeltaB670, whereas 2 nucleotide sub-reduce the possibility of selecting for variants present
among the SIVdeltaB670 quasispecies. SIV-specific stitutions (positions 911 and 997) were present in all
SIVsmm sequences except SIVsmmH4. These results in-primers (Fig. 1A) a1597 and a1601 were used to PCR
amplify a 600-bp product that included the major subgen- dicate that the proviral DNA sequences surrounding the
SIVdeltaB670 major subgenomic splice donor are highlyomic splice donor and gel purified products were sub-
cloned and sequenced (29). As shown in Fig. 1B, the 130 conserved and that the sequences comprising the puta-
tive major subgenomic splice donor are identical to se-nucleotides surrounding the putative major subgenomic
splice donor were highly related to the same sequences quenced SIVsmm proviruses.
The generation of partial cDNAs expected to containin SIVsmmH4, SIVsmm9, and SIVsmPBj14. The SIVdel-
taB670 clones were placed into four groups, repre- splice junctions specific for tat, rev, and nef mRNAs of
SIVdeltaB670 and SIVsmmH4 was accomplished usingsented by clones pB6.gag.2, pB6.gag.3, pB6.gag.6, and
pB6.gag.12, based on the presence or absence of either nested RT-PCR with primer pairs that selectively ampli-
fied across junctions between adjoined exons (Fig. 1A).2 nucleotide substitutions (positions 1007 and 1025) or a
single nucleotide insertion (position 1029). All differences RNA templates were purified either from CEM1174 cells
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infected with an aliquot of SIVdeltaB670 or from the intron leads to increased translation of an indicator gene
in vitro (33) and its removal from a large proportion ofchronically infected H9/smmsmH-4 cell line (24), both
obtained directly from the AIDS Reference and Reagent SIVsmm mRNAs suggests that these viruses utilize this
as a mechanism to regulate viral gene expression. SIV-Repository. The primers for first round amplification were
z3086 and z3087 and the primers for second-round ampli- deltaB670 clones N5 and N6 represent newly character-
ized SIV splice junctions generated by either the removalfications were PCRAR, PCR25, and PCRTAT5*, which
have been described (10). The second round PCRs with of a previously undescribed LTR intron or the removal of
a single 8.2-kb intron bounded by the LTR intron spliceprimer pair PCRAR/PCRTAT5* were performed to in-
crease the sensitivity of generating partial cDNAs con- donor (position 575) and the nef splice acceptor (position
8806). This is the largest intron that could be removedtaining tat splice junctions because tat mRNAs have
been shown to be expressed at low levels (10, 12). cDNA from a SIV mRNA by utilization of documented splice
donors and acceptors, and its removal would be ex-clones were randomly selected and analyzed either by
DNA sequencing or colony hybridization with putative tat pected to disrupt the secondary structure of the SIV TAR
element (33). A similar splice junction between the LTR[5*-AGGGTGTCTCCATGTCTGCAACCGGAGGCC-3*, po-
sitions 6290–6276, 972–958 of SIVmacBK28 (31)] or LTR intron splice donor and rev splice acceptor has been
documented for SIVmac251 (34).intron (5*-TGACCAGGCGGCGACTGCTAGTGCTGGAG-
3*, positions 724–711, 566–552 of SIVmacBK28) splice Among the splice acceptors utilized in nef clones N1–
N7, N9, and in rev clones R1–R5 were two alternativejunction probes, or both. These data are summarized in
Fig. 2. splice acceptors separated by three nucleotides (posi-
tions 8803 and 8806) for the removal of the single intronIndividual clone types identified as having been de-
rived from tat, rev, and nef mRNAs were given designa- in nef transcripts and the second intron in rev transcripts.
A third, alternative splice acceptor in this region was nottions consisting of a letter T, R, or N referring to tat, rev,or
nef, respectively, and a number. The structures of nef detected, as has been described for SIVmac (10, 34) but
examination of a larger number of clones might demon-clones N1 through N4, rev clones R1 through R4, and tat
clones T1 and T2 were predicted to contain the exons strate utilization of such a site. The significance of the
utilization of these alternative splice acceptors remainsshown (Fig. 2), based on comparison of previously pub-
lished SIVmac splice junctions (6, 10, 12, 13) and the unclear. However, it is a highly conserved feature of SIV
splicing as all comprehensive analyses of SIV splicingSIVsmmH4 proviral sequence (24). At least one clone
was obtained in each of these 10 classes, except for R2 have demonstrated such alternative splicing.
Despite the similarities between the patterns of spliceand T2, and in each class, the putative major subgenomic
splice donor (Fig. 1B) was utilized. The tat, rev, nef, and site utilization by SIVdeltaB670 and SIVsmmH4, differ-
ences were also observed and consisted of either theLTR intron splice sites utilized by SIVdeltaB670 and
SIVsmmH4 were also positioned as expected (10, 24) absence of a predominant splice junction for a given
transcript class, the presence of additional exons, or theand were found in consensus splice sites (Fig. 3A; Ref.
32). In addition, the splice donors and splice acceptors utilization of putative alternative splice donor and/or ac-
ceptor sites (Fig. 2). For example, the predominant SIV-comprising SIVdeltaB670 and SIVsmmH4 LTR intron and
tat splice junctions were not only at expected positions, deltaB670 nef/rev clone (clone R1) was represented in
only 4 out of 20 clones, whereas the majority ofbut were identical in sequence to SIVmac splice junc-
tions (10). SIVsmmH4 nef/rev clones were represented in a single
rev clone (R3) obtained as 23 out of 34 clones. In addition,Interestingly, 96% (120 out of 125) of the clones in
these 10 groups had the same intron removed from the SIVdeltaB670 expressed a larger proportion of tat mRNAs
(T4–T7) that contained additional exons. The extra, small5* end of the mRNA that is also removed from a subset
of SIVmac and HIV-2 mRNAs (10, 14). Splicing of the LTR exons present in clones T3–T7 (except clone T6) and
FIG. 2. Structure of SIVdeltaB670 and SIVsmmH4 partial cDNAs containing splice junctions. Adjoined sequences contained in nested RT-PCR
products generated with primer pair PCRAR/PCR25 or PCRAR/PCRTAT5* in the second round of amplification are shown as black boxes. The
remainder of the sequences expected to be present in full-length cDNAs are shown as shaded boxes. Total cellular RNA was isolated from 106
cells and 15 mg was reverse-transcribed using Moloney murine leukemia virus RT and oligo(dt) as cDNA primer (Perkin–Elmer Corp.). PCRs
contained 1 mM each primer, 1.5 mM MgCl2 , 50 mM KCl, 10 mM Tris pH 8.3, and 2.5 U of Taq polymerase per 100-ml reaction and were cycled
30 times at 947 for 30 sec, at 557 for 45 sec, and at 727 for 75 sec. Of the first-round reactions 4 ml was placed in second-round reactions (100 ml).
Ethanol-precipitated PCR products were restriction digested with EcoRI and SphI, agarose gel purified, and ligated to EcoRI/SphI-digested pUC19
following standard recombinant DNA methodologies (30). Nucleotide positions follow that of SIVsmmH4 (24). The sequences of the primers used
in the initial PCR were z3086 (5*-CTGTATTCAGTCGCTCTG-3*, positions 508–525 of SIVsmmH4) and z3087 (5*-TGGTTGGAGGATCTGGTA-3*, posi-
tions 8986– 9003). The numbers of each type of clone obtained from each of the four separate PCRs are shown to the right. The percentage
represented by each clone is given in parentheses. †, Putative splice donors and acceptors, which when aligned with SIVsmmH4, SIVsmmPBj14,
and SIVsmm9, are not predicted to be followed by a GU or preceded by an AG, respectively. ‡, Clones containing previously undocumented splice
junctions involving the LTR intron splice donor.
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FIG. 3. SIVsmm splice donor and splice acceptor sequences and deduced partial amino acid sequences for Rev and Tat. (A) SIVdeltaB670 and
SIVsmmH4 splice junction sequences contained in the clones shown in Fig. 2. Intron sequences for SIVsmmH4 (24) and intron sequences for
SIVdeltaB670 are from clone T9 (for the tat splice acceptor) or a subset of SIVdeltaB670 PCR products containing sequences surrounding the nef
splice acceptor (data not shown). Lowercase letters represent intron sequences extrapolated from the SIVsmmH4 proviral sequence (24). (B)
Alignment of the first coding exon of rev and deduced partial amino acid sequences of SIVdeltaB670 and SIVsmmH4 Rev and Tat proteins encoded
by this exon and resulting from utilization of alternative splice acceptors at positions 8803 or 8806. Underlined are potential enhancers of splicing
of exons, ESEs (35, 36). Dots represent nucleotide or amino acid sequence identity, whereas dashes represent gaps in nucleotide or amino acid
sequences.
N9 are positioned identically to small exons detected in (32). We therefore compared the sequences of all putative
alternative splice donors and splice acceptors to availableSIVmacBK28 mRNAs (10). The small exon in clone T6,
however, ends at the same position in clone T5 and full-length SIVsmm sequences and those sites that, by
extrapolation, did not have predicted GT or AG dinucleo-in a subset of SIVmacBK28 clones (10). Therefore, the
generation of mRNAs containing these exons is a con- tides as their immediate 3* or 5* neighboring nucleotides,
respectively, have been marked with a dagger in Fig. 2.served feature of SIV RNA processing, particularly for tat
mRNAs. Similar exons derived from the 3* end of the pol Of the 20 clones with putative alternative splice sites, 7
(N5, N6, N9, T3–T5) had introns removed that were pre-gene are present in HIV-1 mRNAs, and their positions are
also conserved when splice site utilization by different dicted to be limited by GT and AG sequences and utilized
1 or more splice sites that were observed in legitimatestrains is compared (8, 9).
In addition to the partial cDNA clones generated by tat, rev, or nef cDNAs. An additional 7 clones (N7, T6–T8)
utilized at least 1 splice site found in legitimate tat, rev,RNA splicing at predicted splice donors and acceptors, a
subset of the cDNAs derived from SIVdeltaB670-infected or nef cDNAs but contained other putative splice sites not
predicted to have GU or AG sequences bordering thecells (18 out of 71) appeared to be generated by utilization
of putative alternative splice donors and splice acceptors introns. The last 6 of these clones (N8, N10, N11, R5, and
T9) did not contain previously observed splice sites andor by the inclusion of additional exons, such as for tat
clones T3–T9. The set of 74 SIVsmmH4 partial cDNAs did not have predicted GU or AG sequences bordering
the introns and we cannot rule out the possibility thatcontained only 2 of these types of clones, N9 and T3.
Introns removed from RNA Pol II pre-mRNAs contain GU they were derived from deleted proviruses rather than
alternative splice site utilization.and AG dinucleotides at their 3* and 5* limits, respectively
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Although the positions of rev splice acceptors were splice acceptors for nef as well as for the third exon of
rev (and presumably tat) mRNAs (Fig. 2). HIV-1 is unique,as expected, the nucleotide and deduced amino acid
sequences of SIVdeltaB670 in the first rev coding exon though, in that multiple splice acceptors are utilized in
generating rev splice junctions (8, 9, 15). By characteriz-were unique (Fig. 3B). These sequence differences also
are predicted to change the deduced Tat amino acid ing SIVsmm RNA splicing by uncloned SIVdeltaB670 and
molecularly cloned SIVsmmH4, we have demonstratedsequence which is translated from a /1 reading frame
relative to Rev. In all tat cDNAs the predicted initiation that the patterns of splice site utilization by SIVs are
highly conserved between genetically and pathogenet-codon was the first one following the tat splice acceptor,
whereas in all rev cDNAs, there was an AUG codon 5 ically distinct SIVsmm and SIVmac viruses, and in some
aspects, between these viruses and HIV-1.bases upstream of the predicted initiation codon for both
SIVdeltaB670 and SIVsmmH4, similar to SIVmac RNAs
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